Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market – Industry Trends and Forecast to 2034

Indonesia, Malaysia, Philippines, Thailand and Vietnam Iga Nephropathy Market Analysis and Size

IgA nephropathy, also known as Berger's disease, is a kidney disease that occurs when IgA concentration increases in the kidneys, causing inflammation that damages the kidney tissues. IgA is an antibody-a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is an orphan disease designated as an orphan indication. This disorder is highly prevalent in countries such as Vietnam and Thailand among others.

The rise in IgA nephropathy cases propels market growth as it necessitates an increased focus on R&D and investment in therapeutic solutions. A growing patient population underscores the demand for effective treatments, prompting pharmaceutical companies to innovate and introduce new drug candidates. The expanding market for IgA nephropathy not only attracts heightened R&D expenditure but also stimulates competition among industry players.

Data Bridge Market Research analyzes that the Indonesia, Malaysia, Thailand, Philippines, and Vietnam IgA nephropathy market is expected to reach USD 42,340.41 thousand by 2034 from USD 15,716.44 thousand in 2023, growing with a CAGR of 10.1% in the forecast period of 2024 to 2034.

Market Definition

IgA nephropathy, also known as Berger's disease, is a kidney disease caused by the build-up of IgA deposits in kidneys, which cause inflammation and damage to the kidney tissues. Antibodies such as IgA are proteins produced by the immune system to shield the body from foreign substances, including bacteria and viruses. The complication of this disease is the End Stage Kidney Disease (ESKD), which needs dialysis for treatment. The current treatment is used for preventing the progression of the disease, and the treatment of IgA nephropathy is lengthy, which provides sustainable market growth. Diagnosing this disease is also a challenging task as various urine analyzers, blood tests, and kidney biopsies are performed for the detection. The population is seen to have a high prevalence of IgA nephropathy during the epidemiology studies. In the forecast period, most of the targeted therapies are expected to be approved, which is supposed to increase the market size.

Indonesia, Malaysia, Philippines, Thailand and Vietnam IgA Nephropathy Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

Drivers

• Rise in the Number of IgA Nephropathy Cases

IgA nephropathy, also known as Berger's disease, is a kidney disease that occurs when IgA concentration increases in the kidneys, causing inflammation that damages the kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. It is an orphan disease designated as an orphan indication.

• Increase in the Availability of IgA-Targeted Pipeline Drugs

IgA nephropathy is a disorder that needs to be investigated thoroughly to get a novel and more targeted treatment option. Many pipeline products are currently being developed which are in different phases of clinical trials or under the approval process from regulatory bodies.

The number of pipeline drugs is increasing for IgA nephropathy and some of the potential drug candidates are in the final stage and are going to enter the market in the forecast period, thereby increasing the market size. Thus, an increase in the availability of IgA-targeted pipeline drugs is driving market growth.

Opportunity

• Collaboration among Market Players for Drug Development

The IgA nephropathy market has great potential and can attain lucrative growth in the forecast period. However, the market players and new entrants need to strategically study the opportunities generated by the market to attain a stronghold in the market.

One of the most strategic ways to hold and use the opportunities in the market is the global collaboration to expand the business. Many new entrants in the market and the existing market players collaborate to bring new advanced products to the market.

Restraint/Challenge

• High Cost of IgA Nephropathy Treatment

IgA nephropathy treatment comprises diagnosis and further treatment with a wide range of drugs, including blood pressure-lowering agents, immunosuppressive agents, cholesterol-lowering drugs, and various supplements. The disease diagnosis includes various blood tests, urinalysis, some radioactive tests, and kidney biopsy.

The total cost of treatment or the cumulative expense of diagnosis and treatment is relatively high. The instance given below describes the cost per pocket if reimbursement is not provided, which is a major drawback in emerging countries.

Recent Developments

• In December 2023, Novartis AG performed an investigational iptacopan Phase III study that demonstrated clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G). This development helped the company boost its revenue growth
• In October 2023, Novartis AG’s Phase III clinical study demonstrated a significant proteinuria reduction in patients suffering from IgA nephropathy. The phase III ALIGN study met its primary endpoint, demonstrating the superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis.  IgAN is a progressive kidney disease affecting mostly young adults, and is a major cause of chronic kidney disease and kidney failure worldwide. This development helped the company boost the market growth.

Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market Scope

The Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market is segmented into six notable segments based on disease type, type, population type, route of administration, end user, and distribution channel.

Disease Type

• Primary IgA Nephropathy
• Secondary IgA Nephropathy

On the basis of disease type, the market is segmented into primary IgA nephropathy and secondary IgA nephropathy.

Type

• Diagnosis
• Treatment

On the basis of type, the market is segmented into diagnosis and treatment.  

Population Type

• Adults
• Geriatric
• Pediatric

On the basis of population type, the market is segmented into adults, geriatric, and pediatric.

Route of Administration

• Oral
• Parenteral
• Others

On the basis of route of administration, the market is segmented into oral, parenteral, and others.

End User

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Ambulatory Care Centers
• Home Healthcare
• Others

On the basis of end user, the market is segmented into hospitals, speciality clinics, diagnostic centers, ambulatory care centers, home healthcare, and others.

Distribution Channel

• Retail Sales
• Direct Tenders
• Others

On the basis of distribution channel, the market is segmented into retail sales, direct tenders, and others.

Competitive Landscape and Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA Nephropathy Market Share Analysis

The Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, country presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market.

Some of the major market players operating in the Indonesia, Malaysia, Thailand, Philippines and Vietnam IgA nephropathy market are Sun Pharmaceutical Industries Ltd, Pfizer Inc., Zydus Group, Novartis AG, ARKRAY USA, Inc., and Teva Pharmaceutical USA Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.) and among others.  

SKU-70410